IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD). It is also developing High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitors for the treatment of GA secondary to dry AMD and other age-related retinal diseases, such as wet AMD and idiopathic polypoidal choroidal vasculopathy. The company has a license agreement with the University of Florida Research Foundation (UFRF) and the University of Pennsylvania for the development and commercialization of novel adeno-associated virus (AAV) gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP); and Best disease and other bestrophinopathies. It also has a research agreement with the University of Massachusetts Medical School to utilize the minigene therapy approach to create AAV gene therapy product candidates targeting Leber Congenital Amaurosis type 10 and STGD1; and to evaluate various AAV gene delivery methods for potential application in the eye. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was founded in 2007 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone212-845-8200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$209.98 million
Profitability
Miscellaneous
Employees35
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable
IVERIC bio (NASDAQ:ISEE) Frequently Asked Questions
What is IVERIC bio's stock symbol?
IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE."
How were IVERIC bio's earnings last quarter?
IVERIC bio Inc (NASDAQ:ISEE) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.35) earnings per share for the quarter. View IVERIC bio's Earnings History.
When is IVERIC bio's next earnings date?
What price target have analysts set for ISEE?
3 analysts have issued 1-year target prices for IVERIC bio's shares. Their forecasts range from $1.25 to $1.25. On average, they expect IVERIC bio's share price to reach $1.25 in the next twelve months. This suggests that the stock has a possible downside of 80.9%. View Analyst Price Targets for IVERIC bio.
What is the consensus analysts' recommendation for IVERIC bio?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IVERIC bio.
Has IVERIC bio been receiving favorable news coverage?
News articles about ISEE stock have trended somewhat positive recently, InfoTrie reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. IVERIC bio earned a news impact score of 1.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for IVERIC bio.
Are investors shorting IVERIC bio?
IVERIC bio saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 1,560,000 shares, an increase of 24.8% from the December 31st total of 1,250,000 shares. Based on an average daily volume of 2,060,000 shares, the short-interest ratio is currently 0.8 days. Approximately 4.3% of the shares of the stock are sold short. View IVERIC bio's Current Options Chain.
Who are some of IVERIC bio's key competitors?
Some companies that are related to IVERIC bio include NextCure (NXTC), Portola Pharmaceuticals (PTLA), Myovant Sciences (MYOV), Opko Health (OPK), Akebia Therapeutics (AKBA), Enanta Pharmaceuticals (ENTA), Dermira (DERM), ImmunoGen (IMGN), Odonate Therapeutics (ODT), Applied Therapeutics (APLT), Karyopharm Therapeutics (KPTI), Gossamer Bio (GOSS), Kiniksa Pharmaceuticals (KNSA), Achillion Pharmaceuticals (ACHN) and I-Mab (ARQT).
What other stocks do shareholders of IVERIC bio own?
Who are IVERIC bio's key executives?
IVERIC bio's management team includes the folowing people:
- Dr. David R. Guyer, Exec. Chairman (Age 59)
- Mr. Glenn P. Sblendorio M.B.A., CEO, Pres & Director (Age 63)
- Dr. Samir C. Patel M.D., Co-Founder and Consultant (Age 58)
- Mr. David F. Carroll, Sr. VP, CFO & Treasurer (Age 53)
- Mr. Keith Westby M.B.A., Sr. VP & COO (Age 44)
Who are IVERIC bio's major shareholders?
IVERIC bio's stock is owned by many different of institutional and retail investors. Top institutional investors include Tamarack Advisers LP (6.37%), Renaissance Technologies LLC (2.55%), Perceptive Advisors LLC (2.38%), Acadian Asset Management LLC (2.14%), Connor Clark & Lunn Investment Management Ltd. (1.66%) and Tang Capital Management LLC (0.60%). Company insiders that own IVERIC bio stock include David Francis Carroll, David R Guyer, Glenn Sblendorio and Keith Westby. View Institutional Ownership Trends for IVERIC bio.
Which institutional investors are selling IVERIC bio stock?
ISEE stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Tamarack Advisers LP, Tang Capital Management LLC, Renaissance Technologies LLC, Connor Clark & Lunn Investment Management Ltd., Summit X LLC, Jacobs Levy Equity Management Inc. and Goldman Sachs Group Inc.. Company insiders that have sold IVERIC bio company stock in the last year include David Francis Carroll, David R Guyer and Keith Westby. View Insider Buying and Selling for IVERIC bio.
Which institutional investors are buying IVERIC bio stock?
ISEE stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Schonfeld Strategic Advisors LLC, Credit Suisse AG, Laurion Capital Management LP, Tower Research Capital LLC TRC , Alpine Global Management LLC, California Public Employees Retirement System and Lindbrook Capital LLC. View Insider Buying and Selling for IVERIC bio.
How do I buy shares of IVERIC bio?
Shares of ISEE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is IVERIC bio's stock price today?
One share of ISEE stock can currently be purchased for approximately $6.56.
How big of a company is IVERIC bio?
IVERIC bio has a market capitalization of $273.09 million and generates $209.98 million in revenue each year. The company earns $63.09 million in net income (profit) each year or ($1.67) on an earnings per share basis. IVERIC bio employs 35 workers across the globe.View Additional Information About IVERIC bio.
What is IVERIC bio's official website?
How can I contact IVERIC bio?
IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The company can be reached via phone at 212-845-8200 or via email at [email protected]
MarketBeat Community Rating for IVERIC bio (NASDAQ ISEE)
MarketBeat's community ratings are surveys of what our community members think about IVERIC bio and other stocks. Vote "Outperform" if you believe ISEE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ISEE will underperform the S&P 500 over the long term. You may vote once every thirty days.
